A Retrospective Comparative Study of Sodium Fluoride Na18F-PET/CT and 68Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic Analysis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.1.1. Group M
2.1.2. Group N
2.2. Imaging PET/CT Protocol
2.3. Image Aanalysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Lange, P.H.; Vessella, R.L. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev. 1999, 17, 331–336. [Google Scholar] [CrossRef] [PubMed]
- Alva, A.; Hussain, M. The Changing Natural History of Metastatic Prostate Cancer. Cancer J. 2013, 19, 19–24. [Google Scholar] [CrossRef] [PubMed]
- Scher, H.I.; Sawyers, C.L. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen receptor signaling axis. J. Clin. Oncol. 2005, 23, 8253–8261. [Google Scholar] [CrossRef] [PubMed]
- Saad, F.; Hotte, S.J. Guidelines for the management of castrate-resistant prostate cancer. Can. Urol. Assoc. J. 2010, 4, 380–384. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sathiakumar, N.; Delzell, E.; Morrisey, M.A.; Falkson, C.; Yong, M.; Chia, V.; Blackburn, J.; Arora, T.; Kilgore, M.L. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: A population-based analysis of US Medicare beneficiaries, 1999–2006. Prostate Cancer Prostatic Dis. 2011, 14, 177–183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Haberkorn, U.; Eder, M.; Kopka, K.; Babich, J.W.; Eisenhut, M. New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clin. Cancer Res. 2016, 22, 9–15. [Google Scholar] [CrossRef] [Green Version]
- Luining, W.I.; Cysouw, M.C.F.; Meijer, D.; Hendrikse, N.H.; Boellaard, R.; Vis, A.N.; Oprea-Lager, D.E. Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer. Cancers 2022, 14, 1169. [Google Scholar] [CrossRef]
- Alberts, I.L.; Seide, S.E.; Mingels, C.; Bohn, K.P.; Shi, K.; Zacho, H.D.; Rominger, A.; Afshar-Oromieh, A. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: A systematic review and network meta-analysis. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 2978–2989. [Google Scholar] [CrossRef]
- Von Eyben, F.E.; Kairemo, K. Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer. Nucl. Med. Commun. 2014, 35, 221–230. [Google Scholar] [CrossRef]
- Alongi, P.; Laudicella, R.; Lanzafame, H.; Farolfi, A.; Mapelli, P.; Picchio, M.; Burger, I.A.; Iagaru, A.; Minutoli, F.; Evangelista, L. PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature. Cancers 2022, 14, 1770. [Google Scholar] [CrossRef]
- Segall, G.; Delbeke, D.; Stabin, M.G.; Even-Sapir, E.; Fair, J.; Sajdak, R.; Smith, G.T. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J. Nucl. Med. 2010, 51, 1813–1820. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mogensen, A.W.; Petersen, L.J.; Torp-Pedersen, C.; Nørgaard, M.; Pank, M.T.; Zacho, H.D. Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: A nationwide cohort study. BMJ Open 2022, 12, e058898. [Google Scholar] [CrossRef] [PubMed]
- Etchebehere, E.C.; Araujo, J.C.; Fox, P.S.; Swanston, N.M.; Macapinlac, H.A.; Rohren, E.M. Prognostic Factors in Patients Treated with223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. J. Nucl. Med. 2015, 56, 1177–1184. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Apolo, A.B.; Lindenberg, L.; Shih, J.H.; Mena, E.; Kim, J.W.; Park, J.C.; Alikhani, A.; McKinney, Y.Y.; Weaver, J.; Turkbey, B.; et al. Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. J. Nucl. Med. 2016, 57, 886–892. [Google Scholar] [CrossRef] [Green Version]
- Joensuu, T.; Joensuu, G.; Kairemo, K.; Kiljunen, T.; Riener, M.; Aaltonen, A.; Ala-Opas, M.; Kangasmäki, A.; Alanko, T.; Taipale, L.; et al. Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation. Anticancer Res. 2016, 36, 6439–6448. [Google Scholar] [CrossRef]
- Ahmadzadehfar, H.; Rahbar, K.; Baum, R.P.; Seifert, R.; Kessel, K.; Bögemann, M.; Kulkarni, H.R.; Zhang, J.; Gerke, C.; Fimmers, R.; et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 113–122. [Google Scholar] [CrossRef]
- Kairemo, K.; Kangasmäki, A.; Kappadath, S.C.; Joensuu, T.; Macapinlac, H.A. A retrospective analysis of sodium fluoride Na18F-PET/CT and 68Ga-PSMA-11 PET/CT in the skeletal metastases in metastatic prostate cancer using a volumetric 3-D analysis. J. Nucl. Med. 2017, 58, 756. [Google Scholar]
- Kairemo, K.; Kappadath, S.C.; Joensuu, T.; Macapinlac, H.A. A Retrospective Comparative Study of Sodium Fluoride (NaF-18)-PET/CT and Fluorocholine (F-18-CH) PET/CT in the Evaluation of Skeletal Metastases in Metastatic Prostate Cancer Using a Volumetric 3-D Radiomics Analysis. Diagnostics 2021, 11, 17. [Google Scholar] [CrossRef]
- Rohren, E.M.; Etchebehere, E.C.; Araujo, J.C.; Hobbs, B.P.; Swanson, N.M.; Everding, M.; Moody, T.; Macapinlac, A. Deter-mination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. J. Nucl. Med. 2015, 56, 1507–1512. [Google Scholar] [CrossRef] [Green Version]
- Rawlings, N.D.; Barrett, A.J. Structure of membrane glutamate carboxypeptidase. Biochim. Biophys. Acta 1997, 1339, 247–252. [Google Scholar] [CrossRef]
- O’Keefe, D.S.; Bacich, D.J.; Huang, S.S.; Heston, W.D.W. A Perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies. J. Nucl. Med. 2018, 59, 1007–1013. [Google Scholar] [CrossRef] [PubMed]
- Afshar-Oromieh, A.; Haberkorn, U.; Eder, M.; Eisenhut, M.; Zechmann, C. [68Ga]-Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: Comparison with 18F-FECH. Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 1085–1086. [Google Scholar] [CrossRef] [PubMed]
- Kesler, M.; Kerzhner, K.; Druckmann, I.; Kuten, J.; Levine, C.; Sarid, D.; Keizman, D.; Yossepowitch, O.; Even-Sapir, E. Staging 68Ga-PSMA PET/CT in 963 consecutive patients with newly diagnosed prostate cancer: Incidence and characterization of skeletal involvement. Eur. J. Pediatr. 2021, 49, 2077–2085. [Google Scholar] [CrossRef]
- Hofman, M.S.; Emmett, L.; Violet, J.; Zhang, A.; Lawrence, N.J.; Stockler, M.; Davis, I.D. TheraP: A randomized phase 2 trial of (177) Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU Int. 2019, 124, 5–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hofman, M.S.; Emmett, L.; Sandhu, S.; Iravani, A.; Joshua, A.M.; Goh, J.C.; Pattison, D.A.; Tan, T.H.; Kirkwood, I.D.; Ng, S. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A random-ised, open-label, phase 2 trial. Lancet 2021, 397, 797–804. [Google Scholar] [CrossRef] [PubMed]
- Sartor, O.; de Bono, J.; Chi, K.N.; Fizazi, K.; Herrmann, K.; Rahbar, K.; Tagawa, S.T.; Nordquist, L.T.; Vaishampayan, N.; El-Haddad, G.; et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2021, 385, 1091–1103. [Google Scholar] [CrossRef]
- Even-Sapir, E.; Metser, U.; Mishani, E.; Lievshitz, G.; Lerman, H.; Leibovitch, I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J. Nucl. Med. 2006, 47, 287–297. [Google Scholar]
- Kairemo, K.; Macapinlac, H.A. Sodium Fluoride Imaging in Oncology. In Sodium Fluoride PET/CT in Clinical Use; Kairemo, K., Macapinlac, H., Eds.; Clinicians’ Guides to Radionuclide Hybrid Imaging; Springer: Cham, Switzerland, 2020; pp. 19–26. ISBN1 Print 978-3-030-23576-5. ISBN2 Online 978-3-030-23577-2. [Google Scholar] [CrossRef]
- Kairemo, K.J.A.; Joensuu, T. Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT. Diagnostics 2015, 5, 413–427. [Google Scholar] [CrossRef]
- Kairemo, K.; Milton, D.R.; Etchebehere, E.; Rohren, E.M.; Macapinlac, H.A. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer—A Single Institution Experience. Curr. Radiopharm. 2018, 11, 147–152. [Google Scholar] [CrossRef]
- Zacho, H.D.; Fonager, R.F.; Nielsen, J.B.; Haarmark, C.; Hendel, H.W.; Johansen, M.B.; Mortensen, J.C.; Petersen, L.J. Observer Agreement and Accuracy of 18F-Sodium Fluoride PET/CT in the Diagnosis of Bone Metastases in Prostate Cancer. J. Nucl. Med. 2020, 61, 344–349. [Google Scholar] [CrossRef]
- Fourquet, A.; Rosenberg, A.; Mena, E.; Shih, J.J.; Turkbey, B.; Blain, M.; Bergvall, E.; Lin, F.; Adler, S.; Lim, I.; et al. Comparison of 18 F-DCFPyL, 18 F-NaF, and 18 F-FDG PET/CT I,n a Prospective Cohort of Men with Metastatic Prostate Cancer. J. Nucl. Med. 2022, 63, 735–741. [Google Scholar] [CrossRef] [PubMed]
- Harmon, S.A.; Bergvall, E.; Mena, E.; Shih, J.H.; Adler, S.; McKinney, Y.; Mehralivand, S.; Citrin, D.E.; Couvillon, A.; Madan, R.A.; et al. A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer. J. Nucl. Med. 2018, 59, 1665–1671. [Google Scholar] [CrossRef] [Green Version]
- Lawal, I.O.; Mokoala, K.M.G.; Mahapane, J.; Kleyhans, J.; Meckel, M.; Vorster, M.; Ebenhan, T.; Rösch, F.; Sathekge, M.M. A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases. Eur. J. Nucl. Med. Mol. Imaging 2020, 48, 134–142. [Google Scholar] [CrossRef] [PubMed]
- Pepe, P.; Pennisi, M. Should 68Ga-PSMA PET/CT Replace CT and Bone Scan in Clinical Staging of High-risk Prostate Cancer? Anticancer Res. 2022, 42, 1495–1498. [Google Scholar] [CrossRef] [PubMed]
- Ahmadzadehfar, H.; Matern, R.; Baum, R.P.; Seifert, R.; Kessel, K.; Bögemann, M.; Kratochwil, C.; Rathke, H.; Ilhan, H.; Svirydenka, H.; et al. The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: A WARMTH multicentre study. Eur J. Nucl. Med. Mol. Imaging 2021, 48, 4067–4076. [Google Scholar] [CrossRef] [PubMed]
- Oyen, W.; Sundram, F.; Haug, A.R.; Kairemo, K.; Lewington, V.; Mäenpää, H.; Mortensen, J.; Mottaghy, F.; Virgolini, I.; O’Sullivan, J.M.; et al. Radium-223 Dichloride (Ra-223) for the Treatment of Metastatic Castration-resistant Prostate Cancer: Optimizing Clinical Practice in Nuclear Medicine Centers. J. Onco Pathol. 2015, 3, 1–25. [Google Scholar] [CrossRef]
- Kairemo, K.J.A. PET/Computed Tomography for Radiation Therapy Planning of Prostate Cancer. PET Clin. 2017, 12, 257–267. [Google Scholar] [CrossRef] [PubMed]
- Von Eyben, F.E.; Kairemo, K.; Paller, C.; Hoffmann, M.A.; Paganelli, G.; Virgolini, I.; Roviello, G. 177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Biomedicines 2021, 9, 1042. [Google Scholar] [CrossRef]
No/Age | Gleason Score | TNM | Time of dgn | iPSA | Previous Treatments | Bone Therapies | PSA at PET [µg/l] |
---|---|---|---|---|---|---|---|
1/54 | 9 (5 + 4) | T4N1M1 | VII-2013 | 10 | RP, ADT, Rx | Ra | 0.92 |
2/66 | 7 (4 + 3) | T3aN1M0 | VIII-08 | 7.7 | Rx, ADT, Ch, IT | Sm, D, A | 87.5 |
3/78 | 6 (3 + 3) | T2cN0M0 | VII-11 | 15 | Rx, ADT, Ch | D, A, Ra | 3.6 |
4/54 | 7 (4 + 3) | T3N1M0 | VI-09 | 21 | Rx, ADT, Ch | Z, D | 4.9 |
5/61 | 7 (4 + 3) | T2aN0MX | VII-11 | n.a. | RP, ADT, Ch | Z, Ra, A | 1.39 |
6/60 | 7 (3 + 4) | T3bN0M0 | VI-10 | 13 | RP, ADT, Ch | Ra, A | 0.35 |
7/68 | 7 (4 + 3) | T3bN0M0 | III-15 | 38 | RP, ADT, Ch | A, Ra | 15 |
8/79 | 7 (3 + 4) | T3N0M0 | III-06 | 6.7 | RP, ADT, Rx, Ch | Z, Sm | 0.98 |
9/77 | 9 (4 + 5) | T4NXM1 | II-04 | 490 | ADT, Rx, Ch | Z | 4,39 |
10/66 | 8 (4 + 4) | T4N1M1 | VI-13 | 15 | ADT, Ch | A, Ra, D | 447 |
11/57 | 7 (3 + 4) | T2N1M1 | I-13 | 968 | ADT, Rx, Ch | D, Sm | 3.6 |
12/74 | 5 | T1cN0M0 | II-96 | 16 | RP, ADT, Rx, Ch | D, A | 43.1 |
13/57 | 8 (4 + 4) | T3aN0M0 | III-14 | 58 | Rx, ADT | 2.6 | |
14/76 | 8 (4 + 4) | T2N0M0 | VII-99 | n.a. | Rx, ADT, TURP, Ch | Z | 293 |
I/77 | 8 (4 + 4) | T3N0M0 | VIII-16 | 0.3 | 8.29 | ||
II/65 | 7 (3 + 4) | T3bN0M0 | XI-16 | 17.1 | Rx | 17.1 | |
III/65 | 6 (3 + 3) | T1cN0M0 | II-16 | 6.3 | Rx | 6.3 | |
IV/83 | 9 (4 + 5) | T3N1M1 | XI-11 | 26.7 | ADT, Rx, Ch, IT | A | 16.3 |
V/63 | 7 (4 + 3) | T4N0M0 | I-08 | 28 | RP, Rx, ADT | Z | 1.98 |
VI/68 | 7 (4 + 3) | T3N0M0 | V-09 | 8 | RP, Rx, ADT | Z, Sm | 1.7 |
VII/74 | 9 (5 + 4) | T3N0M0 | XII-13 | 0.48 | ADT, Rx | <0.05 | |
VIII/69 | 7 (4 + 3) | T3N0M0 | II I-10 | 22 | Rx, ADT | Z | 2.05 |
IX/77 | 7 (4 + 3) | T1N0M0 | X-16 | 8.3 | TURP, Rx | 2.23 | |
X/50 | 7 (3 + 4) | T1N0M0 | XI-16 | 8.5 | Rx | 8.5 | |
XI/81 | 6 (3 + 3) | T2bN0M0 | XII-97 | 10.5 | RP, Rx, ADT | 7.94 | |
XII/50 | 7 (3 + 4) | T4N0M0 | I-08 | 36 | RP, Rx | 7.81 |
PSMA > 3 | NaF > 10 | PSMA >3 & NaF > 10 | HU > 600 | PSMA > 3& HU > 600 | NaF > 10 & HU > 600 | PSMA > 3 & NaF > 10 & HU > 600 | |
---|---|---|---|---|---|---|---|
METS (n = 14) | 373 ± 885 | 262 ± 354 | 88.9 ± 170 | 1320 ± 501 | 327 ± 1120 | 54.0 ±110 | 19.9 ± 48.5 |
NO METS (n = 12) | 19.2 ± 8.68 | 21.0 ± 49.3 | 0.050 ± 0.15 | 1231 ± 278 | 7.02 ± 3.53 | 2.29 ± 2.13 | 0.00 ± 0.00 |
p< | 0.0010 | 0.000021 | 0.000020 | 0.55 | 0.000022 | 0.00026 | 0.000003 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kairemo, K.; Kangasmäki, A.; Kappadath, S.C.; Joensuu, T.; Macapinlac, H.A. A Retrospective Comparative Study of Sodium Fluoride Na18F-PET/CT and 68Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic Analysis. Life 2022, 12, 1977. https://doi.org/10.3390/life12121977
Kairemo K, Kangasmäki A, Kappadath SC, Joensuu T, Macapinlac HA. A Retrospective Comparative Study of Sodium Fluoride Na18F-PET/CT and 68Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic Analysis. Life. 2022; 12(12):1977. https://doi.org/10.3390/life12121977
Chicago/Turabian StyleKairemo, Kalevi, Aki Kangasmäki, Srinivasan Cheenu Kappadath, Timo Joensuu, and Homer A. Macapinlac. 2022. "A Retrospective Comparative Study of Sodium Fluoride Na18F-PET/CT and 68Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic Analysis" Life 12, no. 12: 1977. https://doi.org/10.3390/life12121977